SOURCES SOUGHT
A -- Medication Discovery Using Rat Models of Relapse to Drug Self-Administration
- Notice Date
- 2/27/2004
- Notice Type
- Sources Sought
- NAICS
- 541710
— Research and Development in the Physical, Engineering, and Life Sciences
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, CMB, 6101 Executive Blvd., Room 260, Bethesda, MD, 20892-8402
- ZIP Code
- 20892-8402
- Solicitation Number
- Reference-Number-4-8848
- Response Due
- 3/11/2004
- Archive Date
- 3/12/2004
- Point of Contact
- Diane Loeb, Contract Specialist, NIDA/NIH, Phone 301 443-6677, Fax 301 443-7595, - Nancy Hurd, Contracting Officer, Phone (301) 443-6677, Fax (301) 443-7595,
- E-Mail Address
-
dloeb@nida.nih.gov, nh31d@nih.gov
- Description
- The National Institute on Drug Abuse, Division of Treatment Research and Development is seeking capability statements from qualified small business organizations (NAICS 541710 with 500 employees) having in-house capability to develop methodologies and to perform in vivo rodent behavioral pharmacology studies of potential pharmacotherapies for cocaine dependence, as well as potential pharmacotherapies for other drug dependence disorders, using drug self-administration reinstatement models. The objective of this contract is to determine the in vivo efficacy of novel compounds in animal models of relapse, including tests in animals trained to self-administer cocaine such as the ability of a test compound to block footshock reinstatement of responding after a period of experimental extinction. This contract may also go beyond the study of cocaine and include other drugs of abuse, such as but not limited to methamphetamine, nicotine and marijuana. The contractor shall develop methods, design, evaluation, and implementation of protocols. Interested organizations must be able to demonstrate, in a capability statement submitted: 1) extensive experience and competence in the field of drug abuse; 2) scientific experience conducting rodent behavioral pharmacology studies; 3) demonstrated compliance with NIH guidelines on the care and use of laboratory animals; 4) laboratory operating according to the FDA's Good Laboratory Practices Program; and 5) Possess a DEA Research Registration for Schedules II to V. THIS IS NOT A REQUEST FOR PROPOSALS. This notice is for information purposes only and does not commit the Government to any contractual agreement. Interested small business organizations submitting a capability statement in response to this sources sought notice are required to identify their size status. Written capability statements must be received no later than March 11, 2004.
- Web Link
-
Link to FedBizOpps document.
(http://www.eps.gov/spg/HHS/NIH/NIDA/Reference-Number-4-8848/listing.html)
- Record
- SN00533198-F 20040229/040227233956 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |